Jones Healthcare Group’s Qube Pro Wins Prestigious PAC Global Awards
Innovation and Sustainability Lead to Double Award Win for Qube Pro at PAC GlobalLondon, Ontario--(Newsfile Corp. - February 8, 2024)...
Year: 2024
Planet 13 Announces Expansion of Leadership Team and Board
LAS VEGAS, NV / ACCESSWIRE / February 8, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13" or the "Company"),...
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Sai Life Sciences releases its Sustainability Report 2023
Sustainability Report 2023 Sustainability Report 2023 HYDERABAD, India, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sai Life Sciences, a leading global...
A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius
A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius CMR Surgical launches vLimeLite * a new...
SweetWater Brewing and Atlanta Track Club Join Forces to Promote Active Lifestyles
SweetWater Brewing is now the Official Beer Partner of the Atlanta Track Club SweetWater Brewing Company x Atlanta Track Club...
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional...
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -PRINCETON, N.J., Feb. 08,...
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and...
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on...
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
Veru Reports Fiscal 2024 First Quarter Financial Highlights
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight...
Teleflex Announces Fourth Quarter 2023 Earnings Conference Call Information
WAYNE, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth...
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
Safe Supply Streaming Announces Strategic Acquisition of 7% Stake in Leading Harm Reduction Company Safety Strips Tech Corp. and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - Safe Supply Streaming Co. Ltd. ("Safe Supply" or "the Company") (CSE: SPLY)...
AGFA HealthCare’s Enterprise Imaging XERO Viewer is Ranked #1 Best in KLAS in the Universal Viewer Category for 2024
The Best in KLAS report recognizes organizations who support healthcare providers that deliver optimized patient care, and the awards are...
Moelis & Company Reports Fourth Quarter and Full Year 2023 Financial Results; Declares Regular Quarterly Dividend of $0.60 Per Share
Fourth quarter GAAP revenues of $214.9 million; fourth quarter Adjusted revenues of $214.9 million, up 6% from the prior year...
Medexus Announces Fiscal Q3 2024 Results
Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host...
The Frigo Mint Company Tackles Cavity Crisis, Announces Launch of the Frigo Mint
New York, New York--(Newsfile Corp. - February 7, 2024) - Revolutionizing the daily oral care routine, The Frigo Mint Company...
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA...